重大事件
外國發行人報告
6-K
2026-07-21
諾和諾德更新股份回購進度 累計回購逾30億丹麥克朗
AI 繁中摘要
Novo Nordisk 提交 6-K 申報，更新股份回購計劃進度 📊。公司於 2026 年 5 月 6 日啟動一項回購計劃，作為總額最高 150 億丹麥克朗（DKK）、為期 12 個月（由 2026 年 2 月 4 日開始）整體回購的一部分。該計劃授權回購 B 股，金額上限為 112 億丹麥克朗，執行期至 2027 年 2 月 1 日。
最新交易時段（7 月 13 日至 17 日）每日回購 19.5 萬股，每股平均購入價約 322.69 至 333.59 丹麥克朗，五日累計交易價值約 3.19 億丹麥克朗。自計劃啟動以來，累計已回購 1,020 萬股 B 股，總值約 30.53 億丹麥克朗 🔄。
若計入整體回購計劃，自 2 月 4 日起 Novo Nordisk 已累計回購 24,959,179 股 B 股，平均價格每股 274.58 丹麥克朗，總交易價值約 68.53 億丹麥克朗。截至 7 月 17 日，公司持有 42,144,480 股庫存 B 股（面值 0.10 丹麥克朗），相當於總股本的 0.9%。
回購行動反映管理層對現金流及股東回報的信心，對投資者而言屬正面信號，有助於穩定股價並提升每股盈利 🏢。公司預計在未來數月繼續按計劃執行回購，直至達到總額上限。
展開英文正文
6-K 1 f6k_072026.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 20, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 13 July 2026, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 9,225,000 2,734,545,468 13 July 2026 195,000 322.69 62,923,858 14 July 2026 195,000 320.55 62,507,407 15 July 2026 195,000 323.83 63,147,108 16 July 2026 195,000 333.59 65,050,395 17 July 2026 195,000 333.35 65,003,163 Accumulated under the programme 10,200,000 3,053,177,399 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 42,144,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Page 2 of 2 Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 17 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 24,959,179 B shares at an average share price of DKK 274.58 per B share equal to a transaction value of DKK 6,853,177,389. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 [email protected] Liz Skrbkova (US) +1 609 917 0632 [email protected] Investors: Michael Novod +45 3075 6050 [email protected] Sina Meyer +45 3079 6656 [email protected] Max Ung +45 3077 6414 [email protected] Christoffer Togo Solgaard-Tullin +45 3079 1471 [email protected] Alex Bruce +45 3444 2613 [email protected] Mads Berner Bruun +45 3075 2936 [email protected] Ida Schaap Melvold +45 3077 5649 [email protected] Frederik Taylor Pitter (US) +1 609 613 0568 [email protected] Novo Nordisk A/S Investor Relations Novo Allé 1 2880 Bagsværd Denmark Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 43 / 2026 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: July 20, 2026 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer